Protection of chickens from lethal influenza virus infection by influenza A/chicken/Pennsylvania/1/83 virus: characterization of the protective effect.
The influenza A/chicken/Pennsylvania/1/83 (H5N2) virus is the first known example of an influenza virus isolated from a natural infection which contained primarily defective interfering particles (T. M. Chambers and R. G. Webster, J. Virol. 61, 1517-1523, 1987). In chickens, coinoculation of this virus together with the closely related but highly virulent influenza A/chicken/Pennsylvania/1370/83 virus results in reduced mortality compared to virulent virus infection alone (Bean et al., J. Virol. 54, 151-160, 1985). The biological basis of this protective effect has not been established. Protective activity required greater than or equal to 100-fold excess input of protecting virus over virulent virus, functioned effectively during the first generations of virulent virus multiplication, and also functioned against an antigenically heterologous (H7N7) virulent influenza virus. Protection was correlated with the complete inhibition of virulent virus spread to the brain of infected chickens. Plaque-purified chicken/Pennsylvania/1/83 virus depleted of defective interfering particles, and beta-propiolactone-inactivated virus, had no protective effect. These characteristics are consistent with the hypothesis that protection was the result of defective interfering particle-mediated interference with virulent virus multiplication within the respiratory tract of the chicken.
Chambers
T M
TM
Department of Virology and Molecular Biology, St. Jude Children's Research Hospital, Memphis, Tennessee 38101.
Webster
R G
RG
D000818:Animals; D002645:Chickens; D004196:Disease Outbreaks; D009980:Influenza A virus / Q000254:growth & development / Q000472:pathogenicity*; D009976:Orthomyxoviridae Infections / Q000453:epidemiology / Q000517:prevention & control*; D011420:Propiolactone / Q000494:pharmacology; D014481:United States / Q000453:epidemiology; D014765:Viral Vaccines / Q000627:therapeutic use*; D014774:Virulence; D014775:Virus Activation
D014765:Viral Vaccines; D011420:Propiolactone